(Q36886252)

16 August 2017

1 reference

title

Impact of pharmaceutical prior authorisation policies : a systematic review of the literature (English)

1 reference

16 August 2017

1 reference

Jaume Puig-Junoy

1

1 reference

16 August 2017

Iván Moreno-Torres

series ordinal

2

1 reference

16 August 2017

publication date

1 January 2007

1 reference

16 August 2017

1 reference

16 August 2017

volume

25

1 reference

16 August 2017

issue

8

1 reference

16 August 2017

page(s)

637-648

1 reference

https://scigraph.springernature.com/pub.10.2165/00019053-200725080-00002

16 August 2017

exact match

0 references

cites work

Clinical and financial outcomes associated with a proton pump inhibitor prior-authorization program in a Medicaid population

1 reference

12 December 2020

Effects of requiring prior authorization for selected antimicrobials: expenditures, susceptibilities, and clinical outcomes

1 reference

12 December 2020

Differential effect of early or late implementation of prior authorization policies on the use of Cox II inhibitors.

1 reference

12 December 2020

Pharmacy Benefit Forecast for a New Interferon Beta-1a for the Treatment of Multiple Sclerosis: Development of a First-Line Decision Tool for Pharmacy-Budget Planning Using Administrative Claims Data

1 reference

12 December 2020

Home hospitalisation of exacerbated chronic obstructive pulmonary disease patients.

1 reference

12 December 2020

Effects of a prior-authorization policy for celecoxib on medical service and prescription drug use in a managed care Medicaid population

1 reference

12 December 2020

Is prior authorization of topical tretinoin for acne cost effective?

1 reference

12 December 2020

Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors

1 reference

12 December 2020

Pricing and reimbursement of pharmaceuticals in Norway

1 reference

12 December 2020

Evaluation of an automated system for prior authorization: a COX-2 inhibitor example

1 reference

12 December 2020

A retrospective analysis of the revocation of prior authorization restrictions and the use of antidepressant medications for treating major depressive disorder

1 reference

12 December 2020

The physician as perfect agent: a comment

1 reference

12 December 2020

The doctor as double agent: information asymmetry, health insurance, and medical care

1 reference

12 December 2020

Pharmaceutical cost management and access to psychotropic drugs: the U.S. context

1 reference

12 December 2020

Pricing and reimbursement of drugs in Denmark.

1 reference

12 December 2020

Physicians' prescribing responses to a restricted formulary: the impact of Medicaid preferred drug lists in Illinois and Louisiana

1 reference

12 December 2020

Benefits and risks of increasing restrictions on access to costly drugs in Medicaid

1 reference

12 December 2020

Clinical and economic consequences of a reimbursement restriction of nebulised respiratory therapy in adults: direct comparison of randomised and observational evaluations.

1 reference

12 December 2020

Prior-authorization programs for controlling drug spending

1 reference

12 December 2020

Impact of prescription coverage on hospital and physician costs: a case study of medicare beneficiaries with chronic obstructive pulmonary disease.

1 reference

12 December 2020

Prior authorization policies for selective cyclooxygenase-2 inhibitors in Medicaid: a policy review

1 reference

12 December 2020

Pharmacoeconomic Modeling of Prior-Authorization Intervention for COX-2 Specific Inhibitors in a 3-Tier Copay Plan

1 reference

12 December 2020

Impact of NSAIDs prior authorization policy on patients' QoL.

1 reference

12 December 2020

When gatekeepers meet the sentinel: the impact of a prior authorization requirement for cefuroxime on the prescribing behaviour of community-based physicians

1 reference

12 December 2020

Effect of a prior-authorization requirement on the use of nonsteroidal antiinflammatory drugs by Medicaid patients

1 reference

12 December 2020

Medicaid cost containment and access to prescription drugs

1 reference

12 December 2020

Cost effects of restricting cost-effective therapy

1 reference

12 December 2020

How effectively do managed care organizations influence prescribing and dispensing decisions?

1 reference

12 December 2020

Economic impact of cost-containment strategies in third party programmes in the US. Part II.

1 reference

12 December 2020

Effects of restrictive formularies in the ambulatory care setting

1 reference

12 December 2020

Medical and pharmacy expenditures after implementation of a cyclooxygenase-2 inhibitor prior authorization program

1 reference

12 December 2020

Does prior authorization of sibutramine improve medication compliance or weight loss?

1 reference

12 December 2020

10.2165/00019053-200725080-00002

Identifiers

DOI

1 reference

Dimensions Publication ID

16 August 2017

1018026521

0 references

1 reference